Related Experiment Video
Updated: Oct 19, 2025
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.4K
Acetophenone 4-nitrophenylhydrazone inhibits Hepatitis B virus replication by modulating capsid assembly.
Manabu Yamasaki1, Norie Matsuda1, Kazuaki Matoba1
1Institute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, Japan.
Virus Research
|September 23, 2021
Summary
A novel compound, ANPH, selectively inhibits Hepatitis B virus (HBV) replication by promoting empty capsid formation. This discovery offers a new scaffold for developing effective anti-HBV drugs.
Area of Science:
- Hepatology
- Virology
- Medicinal Chemistry
Background:
- Hepatitis B virus (HBV) causes chronic liver disease, cirrhosis, and hepatocellular carcinoma.
- Current nucleos(t)ide analog therapies suppress HBV replication but rarely achieve a complete cure.
- There is a significant unmet need for novel anti-HBV therapeutics.
Purpose of the Study:
- To identify novel selective inhibitors of HBV genome replication.
- To explore new structural scaffolds for anti-HBV drug development.
Main Methods:
- Adenovirus vector-mediated HBV genome transduction was used to establish a model system.
- HepG2.2.15 cells were treated with N-(4-Nitrophenyl)-1-phenylethanone hydrazone (ANPH).
- Viral genome replication, transcription, and translation were assessed. Biochemical assays were performed using truncated HBV core protein.
Main Results:
- ANPH selectively inhibited HBV genome replication in HepG2.2.15 cells.
- ANPH induced the formation of empty HBV capsids lacking pregenomic RNA.
- HBV transcription and translation remained unaffected by ANPH treatment.
- ANPH accelerated the assembly of morphologically intact HBV capsids.
Conclusions:
- ANPH represents a novel structural class of selective HBV replication inhibitors.
- ANPH functions by promoting the formation of empty viral capsids.
- ANPH provides a promising structural scaffold for developing new anti-HBV drugs and chemical probes for HBV core protein research.
